Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 6Prostatic Neoplasms 4Rectal Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Brain Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Astrocytoma 1Advanced Prostate Adenocarcinoma 1

Interventions

Temozolomide 3Carboplatin 3Peripheral Blood Stem Cell Transplantation 2Filgrastim 2ixabepilone 1etoposide phosphate 1entinostat 1cediranib 1carboxyamido-triazole 1Thalidomide 1Sirolimus 1Radiotherapy 1Psychiatric Rehabilitation 1Paclitaxel 1PT-100 dipeptide 1O(6)-benzylguanine 1Microarray Analysis 1Immunohistochemistry 1Ifosfamide 1Gelclair 1Fentanyl 1Etoposide 1Erlotinib Hydrochloride 1Docetaxel 1Dasatinib 1Cyproheptadine 1Cyclophosphamide 1Blotting, Western 1ABT751 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × cediranib × Genitourinary × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡